Retatrutide vs Tirzepatide: One Is Approved, One Is Not

Somewhere between the Reddit threads and the headlines about a "triple agonist," you have probably run into the claim: retatrutide makes tirzepatide look mild. The trial numbers behind that claim are real. So is the fine print, and the fine print changes what you should actually do about it.

The Short Answer

Tirzepatide is FDA approved, sold as Mounjaro and Zepbound, and available by prescription today. Retatrutide is an investigational drug still in phase 3 trials. It has posted some of the largest average weight loss ever recorded in an obesity study, and you cannot legally buy it anywhere. Every vial sold online as "retatrutide" right now is an unregulated research chemical, not the drug Eli Lilly is testing.

So the comparison most people want to make, which one should I take, is not actually on the table yet. The comparison that is on the table: a medication you can start this month, or a waiting room. That sounds obvious. The internet has made it surprisingly easy to forget.

Three Receptors Instead of Two

Both drugs come from the same family and the same company. Both are peptides, chains of amino acids built to imitate the hormones your gut releases after a meal.

The difference is how many hormone receptors each one activates. Semaglutide, the original in this class, targets one: GLP-1. Tirzepatide targets two, adding GIP, which is part of why its trial results beat semaglutide's. Retatrutide targets three. The third receptor is glucagon, and that addition matters because glucagon signaling nudges your body to burn more energy rather than just want less food.

Appetite down, burn up. Working both sides of the ledger is the theory behind the bigger numbers.

The Trial Numbers, Side by Side

Here is what has actually been measured, with the source attached to each figure.

• Tirzepatide: in the SURMOUNT-1 trial, adults without diabetes on the highest dose lost an average of 20.9% of their body weight over 72 weeks.
• Retatrutide, phase 2: in results published in the New England Journal of Medicine in 2023, the highest dose produced an average loss of 24.2% at 48 weeks. Weight was still trending down when the trial ended.
• Retatrutide, phase 3: in topline results Lilly reported in 2026, adults without diabetes averaged 28.3% at 80 weeks.

Impressive column of numbers. Now the caveats, which are not small. These are different trials, run for different lengths, on different groups of people, so lining the percentages up in a row is a comparison the data only half supports. No head-to-head trial of retatrutide against tirzepatide has been published. And every figure above is an average: some participants lost far more, some far less, and a chart cannot tell you which one you would be.

What the numbers do support is a narrower conclusion. Retatrutide is the strongest weight loss medication ever taken through late-stage trials, and if the remaining studies hold up, it will likely set a new ceiling for this class.

Weight is also only one of the questions being asked of it. Separate phase 3 studies are testing retatrutide in type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and liver disease, with results expected to keep arriving through 2026 and beyond. That breadth is normal for this drug class now, and it is part of why approval takes as long as it does.

The Side Effects Nobody Leads With

The familiar ones come first. Nausea, vomiting, constipation, and diarrhea, concentrated in the weeks after each dose increase. That pattern runs through the entire GLP-1 family, and retatrutide is no exception.

The phase 2 data added one worth knowing about: a rise in resting heart rate that grew with the dose, peaked partway through the trial, and eased afterward. It is one reason the trials escalate the dose slowly, and one of the things regulators will be reading closely in the full phase 3 safety data, which has not been published yet.

Strength cuts both ways. A drug that pulls weight down faster is also a drug your body feels more, and the practical question is never which molecule wins on a chart. It is which dose you can stay on, eat well on, and function on. Plenty of people on tirzepatide never reach the top dose and do fine at the middle ones. The same will be true of whatever comes next.

About the Vials Sold Online

Type retatrutide into a search bar and the suggestions tell a story. Search data shows more people asking where to buy it than asking whether it is approved. That ordering is the problem.

Because there is no approved version, there is no legal supply chain. Compounding pharmacies cannot make it, since compounding starts from an approved drug and no approved drug exists. What fills the gap is a gray market of "research use only" peptide sites selling vials of powder, shipped with no prescription, no pharmacist, and no one legally accountable for what is inside.

Nobody independently verifies the contents of those vials. Nobody verifies the dose. Nobody verifies sterility, which matters for something you are about to inject. The forums walk buyers through mixing the powder with bacteriostatic water at the kitchen counter, and the confidence of those instructions is easy to mistake for safety. The FDA has already spent two years chasing unapproved GLP-1 products; we covered its warning letters to sellers of compounded semaglutide and tirzepatide, and those were copies of drugs that at least had an approved original to copy. A counterfeit of an unfinished drug has no reference point at all.

However the trials turn out, the version of retatrutide worth taking is the one that arrives with a label, a dose, and a prescriber. That one does not exist yet.

What to Do While You Wait

If your weight is the problem you are trying to solve, waiting one to two years for a stronger molecule is a strategy with a real cost, because the medications available now already work well. Tirzepatide's 20.9% average is bariatric-surgery territory. For most people the limiting factor is never the ceiling of the drug. It is everything around the drug: dosing, nutrition, muscle, and follow-through.

Pedro Gonzalez, MD, our Medical Director, puts the medication in its place this way: "My goal is for you to not need a GLP-1 the rest of your life, if possible. They're fantastic tools for healing... We use them as a tool. We don't use it as the only solution to the problem."

That is also why the strongest-drug framing misses what matters most. Faster weight loss pulls harder on lean mass, and muscle and bone are the part of the loss nobody sees on a bathroom scale. A more powerful molecule makes measuring that trade-off more important, not less. In our medical weight loss program, body composition gets scanned at every visit and compared against your own baseline, so fat loss and muscle loss stop being one blurred number.

And some stubborn weight is not a GLP-1 problem in the first place. Thyroid, insulin resistance, and hormone shifts all sit upstream of the scale, which is why testing comes before prescribing.

Common Questions

Is retatrutide FDA approved?

No. Retatrutide is in phase 3 trials. Eli Lilly reported strong topline results in 2026 but the FDA has not approved it, and it cannot be legally sold, prescribed, or compounded in the United States.

When will retatrutide be available?

No date exists yet. As of late August 2026, Lilly has not announced an approval, and the drug still has to move through filing and FDA review. Even on a fast path, pharmacy availability lands in 2027 at the earliest, and later is plausible.

Is retatrutide better than tirzepatide?

Its trial averages are higher, 24.2% at 48 weeks in phase 2 and 28.3% at 80 weeks in reported phase 3 topline results, against tirzepatide's 20.9% at 72 weeks. But no head-to-head trial exists, the full safety data is not published, and "better" for you depends on tolerability and availability. Today, tirzepatide is the strongest option you can actually be prescribed.

Who makes retatrutide?

Eli Lilly, the same company behind tirzepatide (Mounjaro and Zepbound). Anything sold as retatrutide by anyone else is a gray-market research chemical with no verified contents.

How much will retatrutide cost?

Lilly has not announced a price, and no insurance coverage decisions exist for a drug that is not approved. The honest answer is that nobody knows yet, and any site quoting you a retatrutide price today is selling something else.

Can I switch from tirzepatide to retatrutide when it comes out?

If it is approved, switching would be a decision to make with your provider based on your results, your side effects, and the approved dosing at the time. Transitions between medications in this class are already routine; we wrote about how switching from semaglutide to tirzepatide works in practice.

Start Feeling Like Yourself Again

The next drug is always coming. Your energy, your joints, and your bloodwork are here now, and the tools available today are better than anything that existed five years ago. Our providers have guided more than 3,000 patients through testing first, prescriptions second, and the difference shows in what patients keep: strength, muscle, and results that outlast the medication.

Book your first visit and find out what your labs say before you pick a molecule.